Biomarkers Correlation With Volemia (ENVOL)
The purpose of this study is to determine whether the Biomarkers (pro adrenomedullin (MR proADM), pro arginin vasopressin (CT proAVP), pro atrial natriuretic peptid (MR proANP), Pro Endothelin) changes at Day 2, Day 5 and Day 7 of ICU admission are correlated with Intravascular volume assessed by Cr 51 on red blood cells (Day 2 and Day 7) and by I 125 on albumine Day 7. The correlation of these Biomarkers are also evaluted with other markers such as erythropoietin and catecholamines. 80 ICU patients are included.
Non Traumatic Post Surgery
Poly Trauma Patients Without Heart Failure
Other: Biomarkers, red blood cells and plasma assessment
|Study Design:||Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
|Official Title:||Predictive Value of Biomarkers on Volemia, Extra and Intra Vascular Varation and Hydroelectrolytic Disorders in Different ICU Patients|
- Predictive value of biomarkers changes in Volemia variation [ Time Frame: at Day 2, Day 5 and Day 7 of ICU admission ] [ Designated as safety issue: No ]Correlation with total blood volume(assessed by Cr 51) and biomarkers(Mr proADM, Mr proANP, CT proAVP and proendothelin)changes
- Predictive value of biomarkers changes with efficient volemia, fluid managements and other Markers such erythropoietin [ Time Frame: at Day 2, Day 5 and Day 7 of ICU admission ] [ Designated as safety issue: No ]Correlation with efficient volemia and Biomarkers ( Mr proADM, Mr proANP, CT proAVP and proendothelin)changes.
- Predictive value of Biomarkers with APACHE II and SOFA score and Prognosis at ICU discharge [ Time Frame: at Day 2 , Day 5 and Day 7 of ICU admission and at discharge ] [ Designated as safety issue: No ]Correlation of Biomarkers changes with APACHE II and SOFA score and Mortality at Day 2, Day 5 and Day 7 of their ICU admission and at ICU discharge.
|Study Start Date:||March 2012|
|Estimated Study Completion Date:||March 2014|
|Estimated Primary Completion Date:||January 2014 (Final data collection date for primary outcome measure)|
|Experimental: Biomarkers, total blood volume||Other: Biomarkers, red blood cells and plasma assessment|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01858675
|Contact: Bernard Vigué, Dr MD PHD||+33 1 45 21 34 firstname.lastname@example.org|
|Le Krémilin Bicêtre, Ile de France, France, 94 275|
|Contact: Bernard Vigué, Dr MD PHD +33 1 45 21 34 45 email@example.com|
|Sub-Investigator: Pierre- Etienne Leblanc, DR MD|
|Principal Investigator: Bernard Vigué, Dr MD PHD|